- $1.38bn
- $2.23bn
- $1.89bn
- 89
- 81
- 71
- 94
2019 December 31st | 2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | 10-K | 10-K | 10-K | 10-K | 10-K |
Standards: | USG | USG | USG | USG | USG |
Status: | Final | Final | Final | Final | Final |
Revenue | |||||
Total Revenue | 1,476 | 1,136 | 1,547 | 2,031 | 1,894 |
Cost of Revenue | |||||
Gross Profit | 390 | 292 | 387 | 449 | 451 |
Selling / General / Administrative Expenses | |||||
Research And Development | |||||
Unusual Expense / Income | |||||
Other Operating Expenses | |||||
Total Operating Expenses | 1,329 | 1,062 | 1,318 | 1,834 | 1,689 |
Operating Profit | 147 | 74.4 | 229 | 197 | 205 |
Total Net Non Operating Interest Income / Expense | |||||
Total Net Non Operating Interest Income / Expense | |||||
Other Net Non Operating Costs | |||||
Net Income Before Taxes | 120 | 25.8 | 186 | 157 | 163 |
Provision for Income Taxes | |||||
Net Income After Taxes | 86.4 | 17.7 | 134 | 106 | 103 |
Equity in Affiliates | |||||
Net Income Before Extraordinary Items | |||||
Net Income | 86.9 | 18.2 | 135 | 106 | 104 |
Adjustments to Net Income | |||||
Income Available to Common Shareholders Excluding Extraordinary Items | |||||
Income Available to Common Shareholders Including Extraordinary Items | |||||
Dilution Adjustment | |||||
Diluted Net Income | 86.9 | 18.2 | 135 | 106 | 104 |
Diluted Weighted Average Shares | |||||
Basic EPS Including Extraordinary Items | |||||
Diluted EPS Including Extraordinary Items | |||||
Diluted EPS Excluding Extraordinary Items | |||||
Normalised Income Before Taxes | |||||
Normalised Income After Taxes | |||||
Normalised Income Available to Common Shareholders | |||||
Diluted Normalised EPS | 1.48 | 0.423 | 1.23 | 1.73 | 1.73 |
Dividends per Share |